162 -6 (80) 2025 - Utaev A.Zh., Narzikulov R.M. - ANALYSIS OF DERMATOLOGIC COMPLICATIONS OF ONCOLOGIC IMMUNOTHERAPIES

ANALYSIS OF DERMATOLOGIC COMPLICATIONS OF ONCOLOGIC IMMUNOTHERAPIES

Utaev A.Zh. - Chief physician of Samarkand regional branch of the Republican Specialized Dermatovenerological and Cosmetology Scientific and Practical Medical Center

Utaev A.Zh., Narzikulov R.M. - State Medical University

Resume

In recent years, immunotherapy using checkpoint inhibitors (PD-1, PD-L1, CTLA-4) has firmly entered the clinical practice of oncology and demonstrated a significant improvement in survival rates in patients with advanced cancer. However, along with high efficacy, there is also an increase in the number of side effects, primarily on the skin, which requires increased attention from specialists. The aim of this study is a comprehensive analysis of dermatologic complications associated with immunotherapy, including their frequency, clinical forms, timing of appearance and tactics of correction. The study presents data from a retrospective analysis of 72 cases of immunotherapy use in melanoma, non-small cell lung cancer and renal cell cancer. Dermatologic complications were found in 66.7% of patients, with maculopapular rashes, pruritus, and psoriasiform reactions being the most common. The correlation between the type of therapy (mono- or combined) and the severity of skin manifestations was also revealed. Approaches to the treatment of such complications are presented and the necessity of dermatologic monitoring is substantiated. Scientific novelty consists in systematization of dermatological adverse reactions in real clinical practice and identification of risk factors that increase the probability of their occurrence. The practical significance of the study consists in the formation of clinical recommendations for the diagnosis and management of skin complications during immunotherapy, which allows to increase treatment adherence and improve prognosis in cancer patients

Keywords: immunotherapy, dermatologic complications, oncology, immune inhibitors, cutaneous adverse reactions, PD-1, CTLA-4

First page

837

Last page

840

For citation:Utaev A.Zh., Narzikulov R.M. - ANALYSIS OF DERMATOLOGIC COMPLICATIONS OF ONCOLOGIC IMMUNOTHERAPIES//New Day in Medicine 6(80)2025 837-840 https://newdayworldmedicine.com/en/new_day_medicine/6-80-2025

List of References

  1. Postow M.A., Sidlow R., Hellmann M.D. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168.
  2. Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy. Am J Clin Dermatol. 2018;19(3):345–361.
  3. Coleman E., Ko C., Dai F., et al. Inflammatory skin adverse events associated with immune checkpoint blockade therapy: a systematic review. J Am Acad Dermatol. 2020;82(5):1195–1203.
  4. Teulings H.E., Limpens J., Jansen S.N., et al. Vitiligo-like depigmentation in patients with stage III–IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773–781.
  5. Толибов М. М. и др. Изучение кожных проявлений при вич-инфекции //news in health care. – 2025. – Т. 2. – №. 4. – С. 24-26.
  6. Мухаммадиев А. А., Толибов М. М. Клиническое значение, прогноз и эффективность лечения пищевой аллергии у маленьких детей с атопическим дерматитом //news in health care. – 2025. – Т. 2. – №. 4. – С. 19-23.

    file

    download